Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 819-828

  Malka, David ^a   Cervera, Pascale ^b   Foulon, Stéphanie ^a   Trarbach, Tanja ^c   de la Fouchardière, Christelle ^d   Boucher, Eveline ^e   Fartoux, Laetitia ^b   Faivre, Sandrine ^f   Blanc, Jean Frédéric ^g   Viret, Frédéric ^h   Assenat, Eric ⁱ   Seufferlein, Thomas ^j   Herrmann, Thomas ^k   Grenier, Julien ^l   Hammel, Pascal ^p   Dollinger, Matthias ^m   André, Thierry ⁿ   Hahn, Philipp ^o   Heinemann, Volker ^p   Rousseau, Vanessa ^a   Ducreux, Michel ^a   Pignon, Jean Pierre ^a   Wendum, Dominique ^b   Rosmorduc, Olivier ^b   Greten, Tim F ^q   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL SAINT ANDRÉ   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CENTRE VAL D AURELLE   (France)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l HENRI MONDOR HOSPITAL   (France)

^m MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^p UNIVERSITY OF MUNICH   (Germany)

^q HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER GROWTH; CANCER SURVIVAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GALLBLADDER CARCINOMA; HUMAN; HYPERSENSITIVITY; HYPOMAGNESEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VATER PAPILLA CARCINOMA; VOMITING;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA; CHOLANGIOCARCINOMA; COMMON BILE DUCT NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MUTATION; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84903537674     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70212-8     Document Type: Article

References (30)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM Biliary tract cancers. N Engl J Med 1999, 341:1368-1378.
2. Eckel F, Schmid RM Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96:896-902.
3. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.
4. André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008, 99:862-867.
5. Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006, 95:848-852.
6. Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010, 65:641-647.
7. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gallbladder cancer: a randomized controlled study. J Clin Oncol 2010, 28:4581-4586.
8. Sato Y, Harada K, Kizawa K, et al. Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol 2005, 166:49-60.
9. Yoon J-H, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002, 122:985-993.
10. Lee CS, Pirdas A Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract 1995, 191:1087-1091.
11. Yoon J-H, Gwak G-Y, Lee H-S, Bronk SF, Werneburg NW, Gores GJ Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004, 41:808-814.
12. Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010, 10:631.
13. Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010, 11:1142-1148.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Pocock ST, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
16. Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2010, 21:1537-1545.
17. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006 Cancer Therapy Evaluation, (accessed Feb 12, 2014). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
18. Lévi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86:1608-1617.
19. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
20. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655.
21. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
22. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-the UK ABC-01 study. Br J Cancer 2009, 101:621-627.
23. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010, 103:469-474.
24. Lee J, Park SH, Chang H-M, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012, 13:181-188.
25. Chen L-T, Chen J-S, Chao Y, et al. KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): the TCOG T1210 trial. Proc Am Soc Clin Oncol 2013, 31(suppl):4018. (abstr).
26. Jensen LH, Lindebjerg J, Ploen J, Hansen TF, Jakobsen A Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 2012, 23:2341-2346.
27. Malats N, Porta M, Piñol JL, Corominas JM, Rifà J, Real FX Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J Clin Oncol 1995, 13:1679-1686.
28. Hezel AF, Deshpande V, Zhu AX Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010, 28:3531-3540.
29. Balosso J, Bartolomeu A, Bedenne L, et al. Essai de phase II multicentrique randomisé comparant une radiochimiothérapie (RTCT) à une chimiothérapie seule (CT) associant la gemcitabine et l'oxaliplatine dans les cancers des voies biliaires localement avancés non résécables (FFCD9902) (accessed Feb 14, 2014). http://www.snfge.org/content/essai-de-phase-ii-multicentrique-randomise-comp.
30. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006, 24:3069-3074.